Related Experiment Videos
Cost considerations in the pharmacological prevention and treatment of stroke
A V Alexandrov1, L T Smurawska, W Bartle
1Stroke Research Unit, Sunnybrook Health Science Center, University of Toronto, Ontario, Canada.
Insights
Preventing stroke through risk factor modification and medications like aspirin and warfarin is cost-effective. Minimizing complications and hospital stays is crucial for optimizing stroke treatment economics.
Area of Science:
- Neurology
- Health Economics
- Public Health
Background:
- Stroke is a major cause of death and disability globally, incurring significant healthcare costs.
- Effective stroke prevention and treatment strategies are essential for managing healthcare expenditures.
Purpose of the Study:
- To review the cost-effectiveness of various stroke prevention programs and pharmacological interventions.
- To analyze cost considerations and potential savings from acute stroke treatments.
- To evaluate the economic impact of complications and hospital length of stay.
Main Methods:
- Review of cost-effectiveness of risk factor modification programs.
- Analysis of pharmacological interventions including aspirin, ticlopidine, warfarin, heparin, nadroparin, and alteplase.
- Discussion of economic parameters related to acute stroke treatment and complications.
Main Results:
- Stroke prevention programs and certain pharmacological interventions demonstrate cost-effectiveness.
- Reducing complications like intracerebral hemorrhage is vital for the cost benefits of warfarin and alteplase.
- Shorter hospital stays are a key determinant of cost-effective stroke therapies.
Conclusions:
- Cost-effectiveness analysis is critical for guiding stroke prevention and treatment decisions.
- Future stroke therapy trials must incorporate economic parameters like hospital stay duration and resource intensity.
- Optimizing treatment strategies requires balancing efficacy, complication rates, and economic impact.
Abstract:
Stroke remains the leading cause of neurological disability and the third leading cause of death worldwide, consuming a large share of total healthcare expenditures. In this review, we discuss the cost effectiveness of stroke prevention for various risk factor-modification programmes and pharmacological interventions with aspirin (acetylsalicylic acid), ticlopidine and warfarin. Cost considerations and potential cost savings resulting from acute treatment are discussed for parenterally administered anticoagulants, such as heparin and nadroparin, and for intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; r-tPA). Patients with multiple risk factors for stroke require more aggressive prevention strategies which are associated with a greater risk of complications. The rates of complications, particularly intracerebral haemorrhage, should be kept low to achieve cost benefits for warfarin and alteplase. Reduced hospital length of stay is the key factor in the implementation of cost-effective stroke therapies. The analysis of future clinical trials of new stroke therapies should also include economic parameters, such as length of hospital stay and intensity of resource usage, to help guide formulary and therapeutic decision.